Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
CK Regeon logo — CK Regeon Inc. is a biotechnology-based company aiming to de...

CK Regeon

CK Regeon Inc. is a biotechnology-based company aiming to develop First-In-Class drugs with clear MOA.

Founded 2016 Korea South Korea South 9 employees Series B Total: $19.50B Biotechnology, Health Care +1

General Information

Company Name CK Regeon
Founded Year 2016
Location Korea South Korea South
Employees 9
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with CK Regeon. To contact CK Regeon, visit ckregeon.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does CK Regeon compare?

A PDF of CK Regeon and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting CK Regeon soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About CK Regeon

CK Regeon Inc. is a biotech-based startup founded in October 2016 in South Korea. The company's focus is on developing First-in-Class drugs to address unmet medical needs, with a particular emphasis on the Wnt/β-catenin pathway related to tissue regeneration. Dr. Kang-Yell Choi, the CEO, has a strong track record in R&D, having received various national awards for research excellence and led significant national drug development projects. The latest milestone for CK Regeon Inc. was a KRW13.50B Series B investment on February 16, 2021, with participation from Korea Development Bank, Yozma Group Korea, KNet Investment Partners, Seoul Bio Hub, and Synergy IB Investment. The startup's approach involves identifying CXXC5 overexpression as a disease marker for conditions where Wnt/β-catenin signaling is suppressed, and developing drug candidates that selectively target patients with this overexpression. Potential targeted diseases include obesity, diabetes, non-alcoholic steatohepatitis (NASH), and topically applicable drugs for promoting hair growth and wound healing. The drugs under development aim to activate the Wnt/β-catenin signaling to restore tissue regeneration processes, offering promise for addressing critical medical challenges.

Business keywords: Drug Development, Wnt/β-catenin pathway, Regenerative Medicine, CXXC5, Therapeutic Effects, Tissue Regeneration, Obesity, Diabetes, NASH, Wound Healing, Hair Growth, Alzheimer's Disease, Translational Research, Medical Innovation

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B KRW13.50B 5
Korea Development Bank Yozma Group Korea KNet Investment Partners
Korea Development Bank, Yozma Group Korea +3
16 Feb 2021
Series A KRW6.00B -
01 Jan 2018

CK Regeon Alternatives & Competitors

View All Alternatives
CK Regeon vs
Biosplice Therapeutics
Biosplice Therapeutics United States

Restore health by delivering first-in-class therapies that harness alternative splicing

Grant
37 employees
Biotechnology, Health Care
Compare CK Regeon vs Biosplice Therapeutics
CK Regeon vs
Surrozen
Surrozen United States

Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicin...

67 employees
Biotechnology, Health Care
Compare CK Regeon vs Surrozen
CK Regeon vs
Obatala Sciences
Obatala Sciences United States

Driving Diversity in Research. Impacting the Future.

Series A
13 employees
Biotechnology, Health Care
View all alternatives

FAQ About CK Regeon

CK Regeon Inc. is a biotechnology-based company aiming to develop First-In-Class drugs with clear MOA.
CK Regeon was founded in 2016.
CK Regeon is headquartered in Korea South.
CK Regeon operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Drug Development, Wnt/β-catenin pathway, Regenerative Medicine and CXXC5.
CK Regeon has approximately 9 employees.
CK Regeon has completed 2 funding rounds, raising a total of $19.50B. The latest funding stage is Series B.
Top alternatives and competitors to CK Regeon include Biosplice Therapeutics, Surrozen, Obatala Sciences, Colzyx, LifeSprout, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CK Regeon and Biosplice Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for CK Regeon, https://bouncewatch.com/company/ck-regeon, updated 24 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes